Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
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
VH5FvMvhK0BeEh3Y
